Adaptive Biotechnologies Clocks 26% Jump In Q4 Revenues

Adaptive Biotechnologies Corp ADPT reported Q4 sales of $37.9 million, +26% Y/Y, beating the estimate of $36.37 million.

  • "As we move into 2022, I am encouraged by the momentum and the multiple shots on goal across our businesses, which could positively inflect the trajectory of the company," said Chad Robins, Co-founder, and CEO.
  • Q4 sequencing revenue increased 81% to $23.1 million from $12.7 million, while development revenue dropped 15% to $14.9 million.
  • Adaptive said that clinical testing volume for its ClonoSeq sequencing assay for the minimal residual disease increased 41% to 6,356 tests in the quarter, from 4,539 tests.
  • Net loss per share grew to $(0.43) from $(0.33) a year ago, and beating the consensus of $(0.45).
  • Adaptive finished the year with $570.2 million in cash and equivalents.
  • The company received FDA Emergency Use Authorization for T-Detect COVID to confirm recent or prior COVID-19 infection with over 30,000 tests ordered.
  • Price Action: ADPT shares traded 1.09% higher at $14.85 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!